Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/1999
10/12/1999US5965139 Chicken infectious anemia virus vaccine
10/12/1999US5965135 HIV-1 virus isolates of a subtype and its differential diagnostics
10/12/1999US5965134 Immunogenic composition against Classical Swine Fever Virus (CSFV)
10/12/1999US5965133 Self-assembling multimeric nucleic acid constructs
10/12/1999CA2012219C D-desosamine retinoic esthers, process for their preparation and use in human or veterinary and in cosmetology
10/07/1999WO1999050418A1 Treatment and diagnosis of staphylococcal infections
10/07/1999WO1999050256A1 Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
10/07/1999WO1999050253A1 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
10/07/1999WO1999050250A1 Hiv inhibiting pyrimidine derivatives
10/07/1999WO1999050230A1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
10/07/1999WO1999049891A1 Compositions and methods for providing a vpr-binding protein to a virion
10/07/1999WO1999049890A1 A preventive and therapeutic vaccine for helicobacter pylori-associated diseases
10/07/1999WO1999049889A1 Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens
10/07/1999WO1999049888A2 Identification of bacterial avirulence genes and their products; vaccines and pharmaceutical compositions containing them
10/07/1999WO1999049886A1 Compositions containing bactericides and digestive enzymes compositions
10/07/1999WO1999049885A2 The use of isolated domains of type iv collagen to modify cell and tissue interactions
10/07/1999WO1999049883A2 Oxidized thymosin beta 4
10/07/1999WO1999049881A2 Application of hsp70 proteins
10/07/1999WO1999049875A1 The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients
10/07/1999WO1999049863A1 Sustained release preparations
10/07/1999WO1999049835A1 An acidified composition for topical treatment of nail and skin conditions
10/07/1999WO1999038888A3 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
10/07/1999WO1999030720A9 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
10/07/1999WO1999029717A3 Postweaning multisystemic wasting syndrome virus from pigs
10/07/1999DE19914474A1 New peptide aldehyde and boronic acid derivatives are proteinase inhibitors useful for treatment of viral infections, especially hepatitis
10/07/1999DE19814925A1 Arzneimittel zur Induktion zytotoxischer T-Zellen Drugs for the induction of cytotoxic T cells
10/07/1999DE19814905A1 Verwendung von Bärentraubenblätter (Arctostaphylos uva ursi)-, Birkenblätter (Betula)-, Schachtelhalmkraut (Equisetum)- und Brennessel (Urtica)-Extrakten Use of bearberry leaves (Arctostaphylos uva ursi) -, birch leaves (Betula) - Horsetail (Equisetum) - and stinging nettle (Urtica) extracts
10/07/1999DE19814814A1 Aqueous or water-soluble composition containing iminophenazine derivative useful for preparing antimycobacterial, immunosuppressant, antiinflammatory and/or antiviral medicaments
10/07/1999DE19814725A1 Verwendung von Echinacea-pallida und Echinacea angustifolia-Extrakten; Use of Echinacea pallida and Echinacea angustifolia extracts; Löwenzahn-/Taraxacum)-Extrakten; Dandelion / Taraxacum) extracts; Spitzwegerich-(Plantago)-Extrakten Spitzwegerich- (Plantago) extracts
10/07/1999DE19813760A1 Activation of natural killer cells to stimulate immune response, especially in treatment of tumors, infections and autoimmune diseases
10/07/1999DE19812940A1 Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung Formulation with papillomavirus-specific protein, its preparation and use
10/07/1999CA2326774A1 An acidified composition for topical treatment of nail and skin conditions
10/07/1999CA2326391A1 Identification of bacterial avirulence genes and their products; vaccines and pharmaceutical compositions containing them
10/07/1999CA2325984A1 Oxidized thymosin beta 4
10/07/1999CA2325735A1 Hsp70 protein for the treatment of tumours, cancer or infectious diseases through nk-cell activation
10/07/1999CA2324864A1 Immune response modulator alpha-2 macroglobulin complex
10/07/1999CA2322203A1 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
10/07/1999CA2321960A1 Treatment and diagnosis of staphylococcal infections
10/07/1999CA2291780A1 The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients
10/06/1999EP0947522A2 Process for the preparation of oenotheine B from Epilobium Parviflorum
10/06/1999EP0947517A1 Cephem derivatives
10/06/1999EP0946744A1 Novel polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes
10/06/1999EP0946730A2 Mutants of streptococcal toxin c and methods of use
10/06/1999EP0946722A1 Human apoptosis-related calcium-binding protein
10/06/1999EP0946714A1 Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine
10/06/1999EP0946592A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus
10/06/1999EP0946580A1 Novel erythromycin derivatives, method of preparation and application as medicines
10/06/1999EP0946579A1 Novel erythromycin derivatives, method for preparing them and their use as medicine
10/06/1999EP0946567A1 Novel counterparts of camptothecin, their application as medicine and pharmaceutical compositions containing them
10/06/1999EP0946558A1 Ethylidene derivatives of tricyclic carbapenems
10/06/1999EP0946555A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them
10/06/1999EP0946541A1 Quinolines and their therapeutic use
10/06/1999EP0946502A1 Sulfonamide interleukin-beta converting enzyme inhibitors
10/06/1999EP0946221A1 Combatting infection in delivery systems
10/06/1999EP0946200A1 Immunization of infants
10/06/1999EP0946193A1 Stabilizers for lyophilized vaccines
10/06/1999EP0946188A1 Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
10/06/1999EP0946177A1 METHOD OF INHIBITING BIOSYNTHESIS OF EIf5A
10/06/1999EP0946176A1 The use of 7-(2-oxa-5,8-diazabicyclo 4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of helicobacter pylori infections and associated gastroduodenal diseases
10/06/1999EP0946159A1 An oil composition of dihydropolyprenols
10/06/1999EP0601108B1 Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects
10/06/1999CN1230989A Embryonic or stem-like cell lines produced by cross species nuclear transplantation
10/06/1999CN1230893A Assembly-deficient herpesvirus vaccine
10/06/1999CN1230549A Escape mutant of surface antigen of hepatitis B virus
10/06/1999CN1045441C Antifungal agents, processes for the preparation thereof, and intermediates
10/06/1999CN1045362C Microbicide compositions containing iodide
10/05/1999US5962686 Fungicides
10/05/1999US5962666 Polynucleotide or its complement which codes for enzyme involved in bacterial protein synthesis; for diagnosis and treatment of chlamydia infections such as urogenital disorders and vision defects; bactericides
10/05/1999US5962660 Compound which suppresses selectin-mediated cellular adhesion; for stable antiinflammatory agents with better bioavailability and greater activity which are easier to synthesize
10/05/1999US5962653 Methods of obtaining antiviral proteins and antiviral peptides from Nostoc ellipsosporum
10/05/1999US5962635 Therapeutic compounds
10/05/1999US5962487 Picornaviral 3c protease inhibitors
10/05/1999US5962479 Psychological and nervous sytem disorders
10/05/1999US5962468 Antibacterial activity
10/05/1999US5962467 Derivatives of swainsonine and their use as therapeutic agents
10/05/1999US5962456 Peptic ulcers
10/05/1999US5962446 Administering protein kinase inhibitors
10/05/1999US5962437 Hepatitis, herpes and aida virus
10/05/1999US5962431 Method of treating papillomavirus using 2',5'-oligoadenylate
10/05/1999US5962430 Analog of Haemophilus Hin47 with reduced protease activity
10/05/1999US5962426 Hybrid
10/05/1999US5962415 Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
10/05/1999US5962411 Human growth hormone variants and methods of administering same
10/05/1999US5962410 Fungicides, antiprotozoa agent
10/05/1999US5962303 The invention relates to polynucleotides and polypeptides of bacterial ?topoisomerase iii.?
10/05/1999US5962298 Influenza vaccine
10/05/1999US5962295 This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses.
10/05/1999US5962259 Response regulator polynucleotides
10/05/1999US5962240 Mycobacterium proteins and applications
10/05/1999US5962217 MSRV1 virus and MSRV2 pathogen and/or infective agent associated with multiple sclerosis, and biopolymer constituents thereof
10/05/1999US5961985 Vaccine and serum for endotoxin associated disease immunization and treatment, detoxified endotoxin, and bacterial mutant
10/05/1999US5961984 Human T-cell lymphotropic virus type I envelope protein and human monoclonal antibodies specific therefor
10/05/1999US5961983 Stable pura vectors and uses therefor
10/05/1999US5961982 Recombinant herpesvirus of turkeys and uses thereof
10/05/1999US5961979 Complex of a mammalian stress protein noncovalently associated with a peptide that is present in a eukaryotic cell infected with said pathogen but not present in said cell when said cell is not infected with said pathogen
10/05/1999US5961976 Monoclonal antibodies characterized by their ability to neutralize in vitro and in vivo primary isolates of human immunodeficiency virus (hiv) and related immunodeficiency viruses.
10/05/1999US5961975 Type I surface antigen associated with staphylococcus epidermidis
10/05/1999US5961973 Binding agent which specifically binds a surface component of a pathogen, for instance the gp120 viral coat protein of the human immunodeficiency virus, and a catalytic moiety
10/05/1999US5961970 Submicron emulsions as vaccine adjuvants
10/05/1999US5961969 Enhancing natural killer cell cytotoxicity.
1 ... 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 ... 1798